JCR Pharmaceuticals (Japan)

Recent papers from JCR Pharmaceuticals (Japan)

1. Comparative DIA Proteomics of Neuroblastoma: Laser-Microdissected FFPE Tumors Versus Cell LinesBiology · 2026
2. Optimized Kilogram-Scale Synthesis and Impurity Identification of ClascoteroneOrganic Process Research & Development · 2026
3. Efficacy and safety of GH treatment in Japanese pediatric patients with SHOX deficiency: an open-label extension studyClinical Pediatric Endocrinology · 2026
4. Translational applicability of human blood-brain barrier spheroid models for the development of brain-penetrant therapeutic antibodiesFluids and Barriers of the CNS · 2026
5. Novel therapy for gastric cancer peritoneal dissemination using genetically modified dental pulp cells and astatine-2112025
6. Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II2025
7. Resolution of extensive Mongolian spots (dermal melanocytosis) in a patient with mucopolysaccharidosis type II undergoing enzyme replacement therapy with pabinafusp alfa: A case reportBrain and Development Case Reports · 2025
8. Combined treatment with mesenchymal stem cells and therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy: a phase 1/2 randomized trialScientific Reports · 2025
9. Adeno-associated virus expressing a blood-brain barrier–penetrating enzyme improves GM1 gangliosidosis in a preclinical modelJournal of Clinical Investigation · 2025
10. Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in JapanOrphanet Journal of Rare Diseases · 2024
11. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trialMolecular Therapy · 2024
12. Efficacy and safety of GH treatment in Japanese children with short stature due to SHOX deficiency: a randomized phase 3 studyClinical Pediatric Endocrinology · 2024
13. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II MiceMolecular Pharmaceutics · 2023
14. Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitroFrontiers in Drug Delivery · 2023
15. Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I miceMolecular Therapy — Methods & Clinical Development · 2023
16. IZCARGOⓇ: the world's first biological drug applied with brain drug delivery technologyDrug Delivery System · 2023
17. In-depth mapping of protein localizations in whole tissue by micro-scaffold assisted spatial proteomics (MASP)Nature Communications · 2022
18. Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzymeMolecular Genetics and Metabolism Reports · 2022
19. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in MucopolysaccharidosesInternational Journal of Molecular Sciences · 2022
20. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 studyGrowth Hormone & IGF Research · 2022